Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation

Journal of Hypertension

Volumn 22, Issue 10, 2004, Pages 1971-1976

  Campbell, Duncan J ^a,d   Zeitz, Christopher J ^b   Esler, Murray D ^c   Horowitz, John D ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

ACE2; Angiotensin I; Angiotensin II; Angiotensin (1 7); Angiotensin (1 9); Angiotensin converting enzyme; Angiotensin converting enzyme (ACE) related carboxypeptidase

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-9]; CAPTOPRIL; CARBOXYPEPTIDASE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FUROSEMIDE; LISINOPRIL; PEPTIDE HORMONE; PERINDOPRIL; PERINDOPRILAT; RAMIPRIL; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY SINUS; ENZYME MECHANISM; FEMALE; HEART FAILURE; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN METABOLISM;

EID: 5044220674     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200410000-00020     Document Type: Article

References (20)

1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9.
2. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275:33238-33243.
3. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-14843.
4. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-828.
5. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 2003;108:1707-1712.
6. Duncan A-M, Kladis A, Jennings GL, Dart AM, Esler M, Campbell DJ. Kinins in humans. Am J Physiol 2000;278:R897-R904.
7. Campbell DJ, Aggarwal A, Esler M, Kaye D. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001; 358:1609-1610.
8. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens 1990;8:715-724.
9. Zeitz CJ, Campbell DJ, Horowitz JD. Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension 2003;41:482-487.
10. Campbell DJ, Duncan A-M, Kladis A. Angiotensin converting enzyme inhibition modifies angiotensin, but not kinin peptide levels in human atrial tissue. Hypertension 1999;34:171-175.
11. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991;18:763-773.
12. Campbell DJ, Kladis A, Duncan A-M. Nephrectomy, converting enzyme inhibition and angiotensin peptides. Hypertension 1993;22:513-522.
13. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449.
14. Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J Pharmacol Exp Ther 1999;289:295-303.
15. 10]-angiotensin I. Peptides 1989; 10:489-492.
16. Zisman LS, Meixell GE, Bristow MR, Canver CC. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 2003;108:1679-1681.
17. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993;268:9496-9503.
18. Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdos EG. Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension 2002;39:976-981.
19. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
20. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, et al. Angiotensin II formation in the intact human heart: Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96:1490-1498.